Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Chronic myeloid leukemia

  • You have access
    The Privileged Scaffold Quinoline in Derivatives With Anticancer Potential Mediated by Late Apoptosis
    DENISE DIEDRICH, ELENILSON F. SILVA, JULIA B. WILLIG, THAÍS C. RUARO, NÁDIA M.G. COUTO, MICKAEL JEAN, GLORIA N.S. SILVA, DIOGO A. PILGER, ALINE R. ZIMMER, PIERRE V. WEGUE and SIMONE C.B. GNOATTO
    Anticancer Research March 2026, 46 (3) 1475-1487; DOI: https://doi.org/10.21873/anticanres.18042
  • You have access
    Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
    UROS MARKOVIC, ANNA BULLA, SALVATORE LEOTTA, STEFANIA STELLA, MARIA LETIZIA CONSOLI, LOREDANA TAMBÈ, CONCETTA CONTICELLO, FRANCESCO DI RAIMONDO and FABIO STAGNO
    Anticancer Research September 2020, 40 (9) 5313-5317; DOI: https://doi.org/10.21873/anticanres.14538
  • You have access
    Teratogenic Effect of Radotinib: Case Report
    JUYOUNG CHEON, JUNG WHAN AHN, KYUNG MIN PARK, GUISERA LEE and YUN SUNG JO
    Anticancer Research December 2016, 36 (12) 6599-6601;
  • You have access
    Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    JAVIER PINILLA-IBARZ, KENDRA SWEET, JOSEPHINE EMOLE and MICHAEL FRADLEY
    Anticancer Research December 2015, 35 (12) 6355-6364;
  • You have access
    Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    NORIYOSHI IRIYAMA, YOSHIHIRO HATTA, SUMIKO KOBAYASHI, YOSHIHITO UCHINO, KATSUHIRO MIURA, DAISUKE KURITA, HITOMI KODAIRA, HIROMICHI TAKAHASHI, YOSHIKAZU IIZUKA, MITSURU INOUE and MASAMI TAKEI
    Anticancer Research October 2015, 35 (10) 5473-5478;
  • You have access
    Outcome of Allotransplants in Patients with Chronic-phase Chronic Myeloid Leukemia Following Imatinib Failure: Prognosis Revisited
    YI-CHANG LIU, HUI-HUA HSIAO, CHAO-SUNG CHANG, TA-CHIH LIU, WEN-CHI YANG, JUI-FENG HSU, CHIUNG-TANG HUANG, SHIH-FENG CHO, CHENG-HAN WU, YU-FEN TSAI and SHENG-FUNG LIN
    Anticancer Research October 2013, 33 (10) 4663-4667;
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire